Minneapolis-based NeoChord develops technology for the delivery of artificial chords to treat mitral valve regurgitation. In the role, Berg oversees the clinical and commercial programs for the transeptal and transapical repair of damaged mitral valve chords.
The company’s DS1000 transapical (TA) chord repair system holds commercial marketing authorization in Europe. Its use spans the placement of more than 5,000 successful neochordae in more than 2,000 patients. The company’s NeXus transseptal (TS) chord repair system incorporates the same proprietary, suture-based anchor elements as DS1000. It’s currently in feasibility clinical trials.
Taking over the oversight of these products, Berg brings with him significant medtech experience over more than 30 years. He most recently served as CEO of Metavention, an intravascular denervation company. The company is currently progressing a renal denervation system to treat hypertension.
Before Metavention, Berg served as CEO of Torax Medical. Torax developed magnetic augmentation for treating gastroesophageal reflux disease. Johnson & Johnson’s Ethicon division eventually acquired Torax and its technology.
“One of the most significant clinical gaps in structural heart innovation is providing patients a treatment option to address mitral regurgitation before the disease progresses to stages where the heart becomes damaged,” Berg said in a news release. “The opportunity to develop a first-line therapy for mitral valve disease, by resolving regurgitation early in the disease state, is incredibly compelling.”
